PA
CLVS

Perceptive Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Perceptive Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-200,000
Closed -$660K – 122
2019
Q1 		$660K Buy
+200,000
New +$5.01M 0.02% 89

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Perceptive Advisors's CLVS Position: Q4 2018 in Review

Perceptive Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 150,000 shares — an estimated $4.41M sold.

Perceptive Advisors first reported a position in CLVS in Q2 2013 and held it in 11 quarters. The position peaked at $11.9M in Q1 2014. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Perceptive Advisors reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Perceptive Advisors sold 150,000 Clovis Oncology, Inc. shares in Q4 2018, an estimated $4.41M.
  • Perceptive Advisors first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 11 quarters.
  • Perceptive Advisors's Clovis Oncology, Inc. position peaked at $11.9M in Q1 2014.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.